Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06602479 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
A Phase 2 study of Migraine, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 488
- Enrollment target
- 20
- Study locations
NCT06602479: Recruiting Phase 2 study of Migraine, sponsored by AbbVie.
NCT06602479 is a Phase 2 study of Migraine that is actively recruiting participants, run by AbbVie. The registered enrollment target is 488 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06602479, a Phase 2 study of Migraine, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 488 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
Primary Outcome
Change in number of MHDs from 4-week baseline to last 4 weeks of treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MEDI0618
Study Locations (20)
Florida
- Homestead Associates in Research, Inc. - Homestead
- Florida Neurology - Lake Mary - Lake Mary
- Flourish Research - Miami, LLC dba Flourish Research - Miami
- BayCare Medical Group Neurology at St. Anthony's Hospital - St. Petersburg
- Santos Research Center, Corp - Tampa - Tampa
Other
- Brain-Soultherapy s.r.o. - Kladno
- Clintrial s.r.o. - Prague
- DADO Medical s.r.o. - Prague
- Axon Clinical s.r.o. - Prague
Alabama
- Flourish - Birmingham - Birmingham
- Tennessee Valley Neurological Associates PC - Huntsville
California
- The Neurology Center of Southern California - Carlsbad Office - La Jolla
- Clinical Research Institute, LCC - Los Angeles
Kentucky
- Norton Neuroscience Institute - Headache Clinic - Louisville
New York
- Modern Migraine, MD - New York
Rhode Island
- Velocity Clinical Research, Providence (East Greenwich) - East Greenwich
South Carolina
- Palmetto Primary Care Physicians Division of Gastroenterology - Summerville - Summerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2027-05-07 |
| Phase | Phase 2 |
What NCT06602479 shows while recruiting
NCT06602479 is an interventional study that assigns participants to a tested intervention. The registered 488 participants enrollment target is mid-sized for trials with a published cap, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06602479 names 20 study sites across 11 states, led by Florida, Other, Alabama.
Frequently Asked Questions
What is clinical trial NCT06602479 about?
NCT06602479 is a clinical study titled "A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine". The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
What is the current status of trial NCT06602479?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 488 participants. The study started on 2024-10-07. Estimated completion is 2027-05-07.
What conditions does trial NCT06602479 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06602479?
The interventions under investigation include: Placebo (DRUG), MEDI0618 (DRUG).
Who is sponsoring clinical trial NCT06602479?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06602479 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06602479's enrollment target sits among peer trials
488 25th of 102 higher than 78 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
RECRUITING · Phase 2
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
RECRUITING · Phase 2
-
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
-
CHOCOlate MeLatonin for AdolescenT MigrainE
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05154669 · 488 participants · Phase 3
Integrating Financial Coaching and Smoking Cessation Coaching
- NCT06532877 · 488 participants · NA
Telephone Support in Advanced Gastrointestinal Cancer
- NCT06794983 · 488 participants · NA
Calls and Coordination for Transitions of Care at Re-entry
- NCT06948435 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI